Haisco(SZ:002653) Xin Lang Cai Jing·2025-09-24 05:54Group 1 - The core viewpoint of the news is that Haikang Technology's stock has seen a significant increase, with a rise of 5.15% to 55.38 CNY per share, and a total market capitalization of 62.021 billion CNY [1] - Haikang Technology, established on August 26, 2005, and listed on January 17, 2012, specializes in the research, development, production, and sales of chemical pharmaceuticals [1] - The main revenue composition of Haikang Technology includes anesthetic products (39.81%), cooperative product-related income (23.59%), other indications (17.02%), parenteral nutrition (10.32%), antiemetics for tumors (8.15%), and other supplementary income (0.86%) [1] Group 2 - Among the top ten circulating shareholders of Haikang Technology, a fund under China Europe Fund has increased its holdings by 5.3574 million shares, bringing its total to 21.2763 million shares, which accounts for 4.42% of the circulating shares [2] - The China Europe Medical Health Mixed A Fund (003095) has achieved a year-to-date return of 28.95% and a one-year return of 48.76% [2] - The fund manager, Ge Lan, has a tenure of 10 years and 242 days, with a total fund size of 39.908 billion CNY, achieving a best return of 126.87% during her tenure [3]